Investor centre


ASX announcements

Company reports & presentations

ASX Report - Quarterly

ASX Report - Half-Yearly  

Appendix 4G - June 2020

Form 20 F & XBRL Reference

Company news and Investor Presentations

Presentation to HC Wainwright & Co

22nd Annual Global Investment Conference


ASX Report - Annual

Response to COVID-19

Lodge Partners Research Report May 2020



30 June 2020

Financial year end

31 August 2020

Full year results

31 December 2020

Half year end

28 February 2021

Half year end results

Corporate governance

Genetic Technologies Limited and its Board are committed to achieving and demonstrating the highest standards of corporate governance. The Board continues to review its corporate governance framework and practices to ensure they meet the interests of shareholders.


The Company and its controlled entities together are referred to as the “Group” in this statement.


Reference is made to the revised Corporate Governance Principles and Recommendations issued and revised from time to time by the ASX Corporate Governance Council. The Board believes that all concepts of the revised Principles and Recommendations have been satisfied, however the Board is realistic with respect to the relative size and nature of the Company and have implemented the Recommendations accordingly. The Company endeavours to ensure exceptions to the guidelines do not have negative impact on the best interests of shareholders.


While in most respects the Company complies with the Recommendations, it is recognised that the development and implementation of policies and practices is an ongoing process that evolves with the needs of the business and its stakeholders.


A description of the Group’s main corporate governance practices is set out below. All of these practices, unless otherwise stated, were in place for the entire year.


Corporate Governance Statement

Company Constitution

Board Charter

Audit Committee Charter

Remuneration Committee Charter

Board Performance Evaluation Policy

Board Protocol

Code of Conduct

Continuous Disclosure Policy

Diversity Policy

Risk and Compliance Policy

Securities Trading Policy

Shareholder Communications Policy

Whistleblower Policy


Share information

ASX share information

The Company has 8,261,726,743 ordinary shares on issue. The Company’s ordinary shares are publicly traded on the Australian Securities Exchange (“ASX”) under the symbol GTG. The Company’s share register is maintained by Computershare Investor Services Pty. Ltd. in Melbourne, Victoria.


For information regarding shares held in the Company, please contact:


Computershare Investor
Services Pty. Ltd.

Yarra Falls
452 Johnston Street,
Abbotsford Vic 3067


Tel: 1 300 850 505 or

Tel: +61 8 9415 4000

Fax: +61 8 9473 2500


For queries go to:


Latest price

share information

The Company’s ordinary shares are also traded, via Level II American Depositary Receipts (“ADRs”), on the Nasdaq Capital Market under the ticker GENE. There are 600 ordinary shares comprising each ADR. The Company’s ADR program is maintained by The Bank of New York Mellon in New York, New York.


For information regarding ADRs held in the Company, please contact:


The Bank of New York Mellon
Level 22, 101 Barclay Street
New York NY 10286


Tel: +1 212 815 2276

Fax: +1 212 571 3050


Latest price

For investor relations,

please contact


© Genetic Technologies Limited 2020